BRPI0817537A2 - 4-[3-(4-ciclopropanocarbonil-piperazina-i-carboni-,-fl uoro-benzil]-2h-ftalazin-1-ona - Google Patents

4-[3-(4-ciclopropanocarbonil-piperazina-i-carboni-,-fl uoro-benzil]-2h-ftalazin-1-ona

Info

Publication number: BRPI0817537A2
Authority: BR; Brazil
Prior art keywords: ftalazin; cypropanocarbonyl; carboni; ona; piperazine
Prior art date: 2007-10-17

Application number

Other languages

English (en)

Inventor

Kathryn Anne Quigley

Ezra John Still

Leonard Jesse Chyall

Original Assignee

Kudos Pharm Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-10-17

Filing date

2008-10-17

Publication date

2015-03-31

2008-10-17 Application filed by Kudos Pharm Ltd filed Critical Kudos Pharm Ltd

2015-03-31 Publication of BRPI0817537A2 publication Critical patent/BRPI0817537A2/pt

2022-04-05 Publication of BRPI0817537B1 publication Critical patent/BRPI0817537B1/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BRPI0817537-3A 2007-10-17 2008-10-17 4-[3-(4-ciclopropanocarbonil-piperazina-1-carbonil)-4-fluoro-benzil]-2h-ftalazin-1-ona, método para obtê-lo, composição farmacêutica compreendendo o mesmo, bem como usos terapêuticos do dito composto BRPI0817537B1 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US98050807P	2007-10-17	2007-10-17
US60/980,508		2007-10-17
PCT/GB2008/003510 WO2009050469A1 (en)	2007-10-17	2008-10-17	4- [3- (4-cyclopropanecarbonyl-piperazine-i-carbonyl) -4 -fluoro-benzyl] -2h-phthalaz in-1-one

Publications (2)

Publication Number	Publication Date
BRPI0817537A2 true BRPI0817537A2 (pt)	2015-03-31
BRPI0817537B1 BRPI0817537B1 (pt)	2022-04-05

Family

ID=40227654

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0817537-3A BRPI0817537B1 (pt)	2007-10-17	2008-10-17	4-[3-(4-ciclopropanocarbonil-piperazina-1-carbonil)-4-fluoro-benzil]-2h-ftalazin-1-ona, método para obtê-lo, composição farmacêutica compreendendo o mesmo, bem como usos terapêuticos do dito composto

Country Status (12)

Country	Link
US (1)	US8183369B2 (pt)
EP (1)	EP2212296B1 (pt)
JP (1)	JP5593229B2 (pt)
KR (1)	KR101598231B1 (pt)
CN (1)	CN101821242B (pt)
AU (1)	AU2008313467B2 (pt)
BR (1)	BRPI0817537B1 (pt)
CA (1)	CA2702429A1 (pt)
ES (1)	ES2530695T3 (pt)
MX (1)	MX2010004028A (pt)
RU (1)	RU2487868C2 (pt)
WO (1)	WO2009050469A1 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UY30639A1 (es) *	2006-10-17	2008-05-31	Kudos Pharm Ltd	Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
EP3925962A1 (en)	2011-05-31	2021-12-22	Rakovina Therapeutics Inc.	Tricyclic inhibitors of poly(adp-ribose) polymerase
ES2751642T3 (es)	2014-04-09	2020-04-01	Kainos Medicine Inc	Compuestos inhibidores de bromodominios y composición farmacéutica que los comprende para prevenir o tratar un cáncer
CN105777651A (zh) *	2015-01-13	2016-07-20	江苏豪森药业集团有限公司	聚腺苷酸二磷酸核糖转移酶抑制剂的晶型及其制备方法和医药用途
CN105753789B (zh) *	2015-04-17	2018-09-25	苏州晶云药物科技有限公司	奥拉帕尼与尿素的共晶及其制备方法
CN105254572A (zh) *	2015-11-09	2016-01-20	北京科莱博医药开发有限责任公司	一种奥拉帕尼的晶型及其制备方法和应用
CN106699672B (zh) *	2015-11-16	2019-10-29	上海博邦医药科技有限公司	一种奥拉帕尼无定型物及其制备方法
ITUB20159206A1 (it) *	2015-12-22	2017-06-22	Olon Spa	Forme cristalline e amorfe di olaparib
US20170204067A1 (en) *	2016-01-14	2017-07-20	Scinopharm Taiwan, Ltd.	Crystalline forms of olaparib and manufacturing processes therefor
CZ201682A3 (cs)	2016-02-15	2017-08-23	Zentiva, K.S.	Solvatované krystalické formy olaparibu, jejich příprava a použití
WO2017153958A1 (en) *	2016-03-11	2017-09-14	Lupin Limited	Novel polymorphic forms and amorphous form of olaparib
CZ2016391A3 (cs)	2016-06-29	2018-01-10	Zentiva, K.S.	Farmaceutická formulace olaparibu
HUE064978T2 (hu)	2016-06-29	2024-04-28	Tesaro Inc	A petefészekrák kezelésének módszerei
EP3515448B1 (en)	2016-09-23	2023-07-05	The Johns Hopkins University	Combinatory treatment strategies of cancer based on rna polymerase i inhibition
CN110944638A (zh)	2017-03-27	2020-03-31	特沙诺有限公司	尼拉帕尼组合物
CN107098862A (zh) *	2017-06-05	2017-08-29	山东裕欣药业有限公司	一种奥拉帕尼二水合物及其制备方法
JP7269227B2 (ja)	2017-09-26	2023-05-08	テサロ，インコーポレイテッド	ニラパリブ処方物
CA3031777A1 (en)	2018-01-31	2019-07-31	Apotex Inc.	Crystalline form of olaparib
US10703728B1 (en)	2019-06-18	2020-07-07	Scinopharm Taiwan, Ltd.	Crystalline form of olaparib and a process for preparing the same
WO2021044437A1 (en)	2019-09-04	2021-03-11	Cipla Limited	Olaparib co-crystals and process of preparation thereof
EP4079295A4 (en) *	2019-12-20	2023-12-06	Samyang Holdings Corporation	COMPOSITION HAVING IMPROVED SOLUBILITY AND BIOAVAILABILITY OF OLAPARIB
CA3176206A1 (en)	2020-04-28	2021-11-04	Debnath Bhuniya	Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors
WO2022058785A1 (en)	2020-09-16	2022-03-24	Nuformix Technologies Limited	Olaparib oxalic acid cocrystals and their pharmaceutical use
CN114249695A (zh) *	2020-09-21	2022-03-29	齐鲁制药有限公司	一种奥拉帕利的新晶型、制备方法及用途
WO2022090938A1 (en)	2020-10-31	2022-05-05	Rhizen Pharmaceuticals Ag	Phthalazinone derivatives useful as parp inhibitors
EP4015375B1 (en)	2020-12-21	2023-03-01	LEONARDO S.p.A.	Indicator for an aircraft capable of hovering and method for assisting performing a manoeuvre for the aforesaid aircraft
US20240199582A1 (en)	2021-04-08	2024-06-20	Rhizen Pharmaceuticals Ag	Inhibitors of poly(adp-ribose) polymerase
CN118696032A (zh)	2021-11-10	2024-09-24	努福米克斯技术有限公司	奥拉帕尼羟基苯甲酸共晶体及其药物用途
WO2026013152A1 (en)	2024-07-09	2026-01-15	Stada Arzneimittel Ag	Pharmaceutical composition comprising olaparib

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB721286A (en)	1951-02-16	1955-01-05	Smith Kline & French Internat	Improvements in or relating to the preparation of tetrahydroisoquinolone derivatives
DE2143745A1 (de)	1971-09-01	1973-03-08	Hoechst Ag	3,4-dihydro-2h-isochinolin-1-thione und verfahren zu ihrer herstellung
US3813384A (en) *	1972-01-17	1974-05-28	Asta Werke Ag Chem Fab	Basically substituted benzyl phthalazone derivatives,acid salts thereof and process for the production thereof
FR2262513A1 (en)	1974-03-01	1975-09-26	Delalande Sa	3,4,5-Triphenyl-delta-1,2,4-oxadiazolines - with bronchodilator, anti-cholinergic, hypertensive, analgesic and sedative activity
US4283539A (en)	1979-12-18	1981-08-11	Pfizer Inc.	Isoquinoline acetic acids
US4665181A (en) *	1984-05-17	1987-05-12	Pennwalt Corporation	Anti-inflammatory phthalazinones
US5215738A (en) *	1985-05-03	1993-06-01	Sri International	Benzamide and nicotinamide radiosensitizers
US5041653A (en) *	1985-05-03	1991-08-20	Sri International	Substituted benzamide radiosensitizers
US5032617A (en) *	1985-05-03	1991-07-16	Sri International	Substituted benzamide radiosensitizers
DE3677322D1 (de) *	1985-11-11	1991-03-07	Asta Pharma Ag	4-benzyl-1-(2h)-phthalazinon-derivate.
DE3640641A1 (de)	1986-11-28	1988-07-14	Thomae Gmbh Dr K	Neue heteroaromatische aminderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE3813531A1 (de)	1987-05-02	1988-11-10	Asta Pharma Ag	Neue 2-aminoalkyl-4-benzyl-1-(2h)-phthalazinon-derivate
CA1334969C (en)	1988-08-19	1995-03-28	Mark James Suto	Substituted dihydroisoquinoline and phthalazine derivatives as potentiators of the lethal effects of radiation and certain chemotherapeutic agents, selected compounds, analogs andprocess
EP0389995B1 (en)	1989-03-28	1995-05-31	Nisshin Flour Milling Co., Ltd.	Isoquinoline derivatives for the treatment of glaucoma or ocular hypertension
DD287032A5 (de)	1989-07-28	1991-02-14	Karl-Marx-Universitaet Leipzig,De	Verfahren zur herstellung von 3-carbamoyl-4-aryl-1,2-di-hydro-isochinolin-1h-onen
US6004979A (en) *	1991-02-07	1999-12-21	Hoechst Marion Roussel	Nitrogenous bicycles
MX9200299A (es) *	1991-02-07	1992-12-01	Roussel Uclaf	Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
EP0502575A1 (en)	1991-03-06	1992-09-09	Merck & Co. Inc.	Substituted 1-(2H)-isoquinolinones
CZ199593A3 (en)	1992-10-02	1994-04-13	Asta Medica Ag	Phthalazinone derivatives exhibiting anti-arrhythmic and analgesic activity and eliminating resistance to a plurality of medicaments (mdr)
EP0634404A1 (en)	1993-07-13	1995-01-18	Rhone Poulenc Agriculture Ltd.	Phtalazin derivatives and their use as pesticides
US5587384A (en) *	1994-02-04	1996-12-24	The Johns Hopkins University	Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
US5648355A (en) *	1994-02-09	1997-07-15	Kos Pharmaceutical, Inc.	Method of treatment of endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin
PT705903E (pt)	1994-08-12	2001-11-30	Myriad Genetics Inc	Mutacoes no gene de susceptibilidade para o cancro da mama e do ovario ligado a 17q
CA2196795C (en)	1994-08-12	2001-04-03	Mark H. Skolnick	Method for diagnosing a predisposition for breast and ovarian cancer
US5589483A (en) *	1994-12-21	1996-12-31	Geron Corporation	Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
IL120264A0 (en)	1996-02-29	1997-06-10	Pfizer	Method of reducing tissue damage associated with non-cardiac ischemia
US6063930A (en) *	1996-04-03	2000-05-16	Merck & Co., Inc.	Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
US5939557A (en) *	1996-04-03	1999-08-17	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
US5872136A (en) *	1996-04-03	1999-02-16	Merck & Co., Inc.	Arylheteroaryl inhibitors of farnesyl-protein transferase
US5883105A (en) *	1996-04-03	1999-03-16	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
US6080870A (en) *	1996-04-03	2000-06-27	Merck & Co., Inc.	Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
US5880140A (en) *	1996-04-03	1999-03-09	Merck & Co., Inc.	Biheteroaryl inhibitors of farnesyl-protein transferase
US5874452A (en) *	1996-04-03	1999-02-23	Merck & Co., Inc.	Biheteroaryl inhibitors of farnesyl-protein transferase
US5859035A (en) *	1996-04-03	1999-01-12	Merck & Co., Inc.	Arylheteroaryl inhibitors of farnesyl-protein transferase
US5854265A (en) *	1996-04-03	1998-12-29	Merck & Co., Inc.	Biheteroaryl inhibitors of farnesyl-protein transferase
US5880128A (en) *	1996-05-08	1999-03-09	Schering Corporation	Carbonyl piperazinyl and piperidinyl compounds
CN1136197C (zh) *	1996-05-30	2004-01-28	霍夫曼-拉罗奇有限公司	新的哒嗪酮衍生物
US5854264A (en) *	1996-07-24	1998-12-29	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
US6060038A (en) *	1997-05-15	2000-05-09	Merck & Co., Inc.	Radiolabeled farnesyl-protein transferase inhibitors
US6635642B1 (en) *	1997-09-03	2003-10-21	Guilford Pharmaceuticals Inc.	PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6514983B1 (en) *	1997-09-03	2003-02-04	Guilford Pharmaceuticals Inc.	Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US6197785B1 (en) *	1997-09-03	2001-03-06	Guilford Pharmaceuticals Inc.	Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US6426415B1 (en) *	1997-09-03	2002-07-30	Guilford Pharmaceuticals Inc.	Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity
WO1999025340A1 (en) *	1997-11-14	1999-05-27	Eli Lilly And Company	Treatment for alzheimer's disease
US20040266784A1 (en) *	1998-06-30	2004-12-30	Snutch Terrance P.	Calcium channel inhibitors comprising benzhydril spaced from piperazine
US6387897B1 (en) *	1998-06-30	2002-05-14	Neuromed Technologies, Inc.	Preferentially substituted calcium channel blockers
US6310059B1 (en) *	1998-06-30	2001-10-30	Neuromed Technologies, Inc.	Fused ring calcium channel blockers
US6943168B2 (en) *	1998-06-30	2005-09-13	Neuromed Technologies Inc.	Calcium channel inhibitors comprising benzhydril spaced from piperazine
US6951862B2 (en) *	1998-06-30	2005-10-04	Neuromed Technologies, Inc.	Calcium channel blockers comprising two benzhydril moieties
US20060084660A1 (en) *	1998-06-30	2006-04-20	Neuromed Technologies Inc.	Calcium channel blockers comprising two benzhydril moieties
US6492375B2 (en) *	1998-06-30	2002-12-10	Neuromed Technologies, Inc.	Partially saturated calcium channel blockers
US20040259866A1 (en) *	1998-06-30	2004-12-23	Snutch Terrance P.	Calcium channel blockers comprising two benzhydril moieties
US6011035A (en) *	1998-06-30	2000-01-04	Neuromed Technologies Inc.	Calcium channel blockers
US7186726B2 (en) *	1998-06-30	2007-03-06	Neuromed Pharmaceuticals Ltd.	Preferentially substituted calcium channel blockers
ITMI981671A1 (it) *	1998-07-21	2000-01-21	Zambon Spa	Derivati ftalazinici inibitori della fosfodisterasi 4
US6677333B1 (en) *	1999-01-26	2004-01-13	Ono Pharmaceutical Co., Ltd.	2H-phthalazin-1-one derivatives and drug containing its derivatives as active ingredient
US6465467B1 (en) *	1999-05-21	2002-10-15	Biovitrum Ab	Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases
US6552016B1 (en) *	1999-10-14	2003-04-22	Curis, Inc.	Mediators of hedgehog signaling pathways, compositions and uses related thereto
US6476048B1 (en) *	1999-12-07	2002-11-05	Inotek Pharamaceuticals Corporation	Substituted phenanthridinones and methods of use thereof
DE19963607B4 (de) *	1999-12-23	2005-12-15	Schering Ag	Verfahren zur Herstellung von 4-(Heteroaryl-methyl) halogen-1(2H)-phthalazinonen
US7498304B2 (en) *	2000-06-16	2009-03-03	Curis, Inc.	Angiogenesis-modulating compositions and uses
IL153115A0 (en) *	2000-06-16	2003-06-24	Curis Inc	Angiogenesis-modulating compositions and uses
CN100400518C (zh)	2000-10-30	2008-07-09	库多斯药物有限公司	2,3-二氮杂萘酮衍生物
US7151102B2 (en) *	2000-10-30	2006-12-19	Kudos Pharmaceuticals Limited	Phthalazinone derivatives
EP1217000A1 (en) *	2000-12-23	2002-06-26	Aventis Pharma Deutschland GmbH	Inhibitors of factor Xa and factor VIIa
US20030073692A1 (en) *	2001-08-07	2003-04-17	Pharmacia & Upjohn S.P.A.	Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
AUPS019702A0 (en) *	2002-01-29	2002-02-21	Fujisawa Pharmaceutical Co., Ltd.	Condensed heterocyclic compounds
AU2003211381B9 (en)	2002-02-19	2009-07-30	Ono Pharmaceutical Co., Ltd.	Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient
US20030195192A1 (en) *	2002-04-05	2003-10-16	Fortuna Haviv	Nicotinamides having antiangiogenic activity
US20040014744A1 (en) *	2002-04-05	2004-01-22	Fortuna Haviv	Substituted pyridines having antiangiogenic activity
EP1501822B1 (en) *	2002-04-30	2010-12-15	Kudos Pharmaceuticals Limited	Phthalazinone derivatives
KR101146806B1 (ko) *	2003-03-12	2012-05-22	메이브릿지 리미티드	프탈라지논 유도체
US7449464B2 (en) *	2003-03-12	2008-11-11	Kudos Pharmaceuticals Limited	Phthalazinone derivatives
JP4431369B2 (ja) *	2003-11-21	2010-03-10	久光製薬株式会社	抗真菌エアゾール外用製剤
BRPI0417056A (pt) *	2003-12-01	2007-02-06	Kudos Pharm Ltd	inibidores de reparo de dano no dna para tratamento de cáncer
WO2005089502A2 (en) *	2004-03-18	2005-09-29	The Brigham And Women's Hospital, Inc.	Methods for the treatment of synucleinopathies
US20050227999A1 (en) *	2004-04-09	2005-10-13	Neuromed Technologies Inc.	Diarylamine derivatives as calcium channel blockers
EP1760071A4 (en)	2004-06-23	2008-03-05	Ono Pharmaceutical Co	COMPOUND WITH S1P RECEPTOR BINDING ABILITY AND USE THEREOF
GB0419072D0 (en) *	2004-08-26	2004-09-29	Kudos Pharm Ltd	Phthalazinone derivatives
US7517870B2 (en) *	2004-12-03	2009-04-14	Fondazione Telethon	Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization
GB0521373D0 (en) *	2005-10-20	2005-11-30	Kudos Pharm Ltd	Pthalazinone derivatives
UY30639A1 (es) *	2006-10-17	2008-05-31	Kudos Pharm Ltd	Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
TW200900396A (en) *	2007-04-10	2009-01-01	Kudos Pharm Ltd	Phthalazinone derivatives

2008
- 2008-10-17 RU RU2010111570/04A patent/RU2487868C2/ru active
- 2008-10-17 KR KR1020107010002A patent/KR101598231B1/ko active Active
- 2008-10-17 BR BRPI0817537-3A patent/BRPI0817537B1/pt active IP Right Grant
- 2008-10-17 CA CA2702429A patent/CA2702429A1/en not_active Abandoned
- 2008-10-17 WO PCT/GB2008/003510 patent/WO2009050469A1/en not_active Ceased
- 2008-10-17 US US12/738,181 patent/US8183369B2/en active Active
- 2008-10-17 CN CN2008801114303A patent/CN101821242B/zh active Active
- 2008-10-17 ES ES08840682T patent/ES2530695T3/es active Active
- 2008-10-17 EP EP08840682.2A patent/EP2212296B1/en active Active
- 2008-10-17 AU AU2008313467A patent/AU2008313467B2/en active Active
- 2008-10-17 MX MX2010004028A patent/MX2010004028A/es active IP Right Grant
- 2008-10-17 JP JP2010529447A patent/JP5593229B2/ja active Active

Also Published As

Publication number	Publication date
MX2010004028A (es)	2010-04-30
EP2212296B1 (en)	2014-12-03
WO2009050469A1 (en)	2009-04-23
KR20100087153A (ko)	2010-08-03
ES2530695T3 (es)	2015-03-04
HK1142065A1 (en)	2010-11-26
RU2010111570A (ru)	2011-11-27
JP2011500655A (ja)	2011-01-06
AU2008313467A1 (en)	2009-04-23
CN101821242B (zh)	2013-07-24
CA2702429A1 (en)	2009-04-23
KR101598231B1 (ko)	2016-02-26
JP5593229B2 (ja)	2014-09-17
CN101821242A (zh)	2010-09-01
AU2008313467B2 (en)	2013-08-29
US8183369B2 (en)	2012-05-22
US20100286157A1 (en)	2010-11-11
BRPI0817537B1 (pt)	2022-04-05
RU2487868C2 (ru)	2013-07-20
EP2212296A1 (en)	2010-08-04

Publication	Publication Date	Title
BRPI0817537A2 (pt)	2015-03-31	4-[3-(4-ciclopropanocarbonil-piperazina-i-carboni-,-fl uoro-benzil]-2h-ftalazin-1-ona
RU2465270C3 (ru)	2017-03-28	Полиморфная форма 4-[3-(4-циклопропанкарбонилпиперазин-1-карбонил)-4-фторбензил]-2н-фталазин-1-она
BRPI0811578A2 (pt)	2014-12-09	Tetramatos substituídos por 3-(2-alcóxi-fenila)
DK2215092T3 (da)	2012-05-07	Substitueret piperidino-dihydrothienopyrimidin
PT2173888T (pt)	2016-11-17	Resumo
EP2170350A4 (en)	2011-09-28	SUBSTITUTED IMIDAZOHETEROCYCLES
ATE501136T1 (de)	2011-03-15	Imidazopyridinone
HRP20170963T1 (hr)	2017-09-22	Modificirani saharidi
DE502008003324D1 (de)	2011-06-01	Heteroaryl-substituierte piperidine
BRPI0814519A2 (pt)	2014-09-30	Organopolissiloxano
BRPI0811451A2 (pt)	2014-11-04	Exopolissacarídeo
BRPI0815547A2 (pt)	2015-02-10	Depsipeptídeos cícliocos
BRPI0812840A2 (pt)	2014-12-09	2-imidazolinas
AT505058A3 (de)	2008-12-15	Türschliesssystem
FR2924738B1 (fr)	2012-11-09	Charniere
DE112008001131A5 (de)	2010-01-28	Hebeeinrichtung
DE112008001216A5 (de)	2010-02-04	Magnetronplasmaanlage
DE112008003094A5 (de)	2010-08-12	Geomatte
ITMI20080151U1 (it)	2008-10-26	Cerniera
DE112008002200A5 (de)	2010-09-23	Sperrsynchronisiervorrichtung
DK2181990T3 (da)	2012-09-10	Piperidinderivat
DE102007038931A8 (de)	2009-06-18	Fadenlagennähwirkstoffe
FR2921682B1 (fr)	2014-03-07	Charniere
DE112008002909A5 (de)	2010-07-29	Verwahrbehältnis
FI20105504L (fi)	2010-05-10	Sarana

Legal Events

Date	Code	Title	Description
2017-04-25	B25G	Requested change of headquarter approved	Owner name: KUDOS PHARMACEUTICALS LIMITED (GB)
2017-05-09	B25G	Requested change of headquarter approved	Owner name: KUDOS PHARMACEUTICALS LIMITED (GB)
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2020-06-23	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]	Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.
2021-05-11	B15K	Others concerning applications: alteration of classification	Free format text: A CLASSIFICACAO ANTERIOR ERA: C07D 237/32 Ipc: C07D 237/32 (2006.01), A61P 25/00 (2006.01), A61P
2021-09-08	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2021-11-03	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2022-02-22	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2022-04-05	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/10/2008, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.